Navigation Links
DOR BioPharma Announces Issuance of European Patent for its LPM(TM) Oral Drug Delivery Technology
Date:7/8/2009

a, Inc.'s current expectations about its future results, performance, prospects and opportunities. Statements that are not historical facts, such as "anticipates," "believes," "intends," or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual events or results in future periods to differ materially from what is expressed in, or implied by, these statements. DOR cannot assure you that it will be able to successfully develop or commercialize products based on its technology, including orBec(R) and LPM(TM), particularly in light of the significant uncertainty inherent in developing vaccines against bioterror threats, manufacturing and conducting preclinical and clinical trials of vaccines, and obtaining regulatory approvals, that its cash expenditures will not exceed projected levels, that product development and commercialization efforts will not be reduced or discontinued due to difficulties or delays in clinical trials or due to lack of progress or positive results from research and development efforts, that it will be able to successfully obtain any further grants and awards, maintain its existing grants which are subject to performance, enter into any biodefense procurement contracts with the US Government or other countries, that the US Congress may not pass any legislation that would provide additional funding for the Project BioShield program, that it will be able to patent, register or protect its technology from challenge and products from competition or maintain or expand its license agreements with its current licensors, or that its business strategy will be successful. Important factors which may affect the future use of orBec(R) for gastrointestinal GVHD include the risks that: the FDA's requirement that DOR conduct additional clinical trials to demonstrate the safety and efficacy of orBec(R) will take a significant amount of time and money to
'/>"/>

SOURCE DOR BioPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Morphotek(R), Inc. Announces a Research Collaboration Agreement with Synageva BioPharma Corporation to Develop Potential Treatments for Cancer and Infectious Disease
2. DOR BioPharma Announces Publication of orBec(R) Clinical Pulmonary Data in Bone Marrow Transplantation
3. Gyros Raises SEK 80 Million to Accelerate the Commercialization of its Gyrolab(R) Systems for the Cost-Efficient Development of Biopharmaceuticals
4. KBI Biopharma Starts Cell Line Generation Process under Vendor Network Agreement for PER.C6(R)
5. Helix BioPharma to Present L-DOS47 Analytical Method Development Findings at 2009 AAPS National Biotechnology Conference
6. Lytix Biopharma and KAEL-GemVax Announce Joint Clinical Trial to Combine LTX-315 and GV1001 Cancer Immunotherapy
7. Wound Management Technologies, Inc. Announced Today That It Has Reached an Agreement in Principal to Acquire BioPharma Management Technologies, Inc.
8. Helix BioPharma Announces Q3 2009 Financial Results and Provides Product Development Update
9. PDL BioPharma Provides Second Quarter 2009 Revenue Guidance of Approximately $125 Million
10. Keryx Biopharmaceuticals Reports Positive Phase 2 Study Results of Zerenex (Ferric Citrate) for the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients
11. Sinobiopharma Applies For Two Chinese Patents For Cisatracurium Besylate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... a way to create a highly sensitive chemical sensor ... imperfections have unique electronic properties that the researchers were ... molecules by 300 times. , The study is available ... . , Amin Salehi- Khojin, asst professor of mechanical ... graduate student and Bijandra Kumar, post doc where they ...
(Date:9/22/2014)... Jose, California (PRWEB) September 22, 2014 ... Chitin and chitosan are natural biopolymers available in ... extracted from easily available resources such as shells ... and chitosan is mainly due to the high ... cellulose. Chitosan finds application in various industries owing ...
(Date:9/22/2014)... Mich., Sept. 22, 2014  Neogen Corporation (Nasdaq: ... the first quarter of its 2015 fiscal year, which ... compared to net income of $7,839,000 in the first ... split effective Oct. 30, 2013, earnings per share in ... year ago. First quarter revenues increased 15% ...
(Date:9/22/2014)... , Sept. 22, 2014 Synageva ... ), a biopharmaceutical company developing therapeutic products for ... Robert Bazemore as Chief Operating Officer.  Reporting ... and Chief Executive Officer, Robert will oversee the ... program, sebelipase alfa for LAL Deficiency, and will ...
Breaking Biology Technology:Graphene imperfections key to creating hypersensitive 'electronic nose' 2Emergence of New Application Areas to Drive the Global Chitin and Chitosan Market, According to New Report by Global Industry Analysts, Inc. 2Emergence of New Application Areas to Drive the Global Chitin and Chitosan Market, According to New Report by Global Industry Analysts, Inc. 3Neogen reports 13% net income increase 2Neogen reports 13% net income increase 3Neogen reports 13% net income increase 4Neogen reports 13% net income increase 5Neogen reports 13% net income increase 6Neogen reports 13% net income increase 7Synageva BioPharma Appoints Robert Bazemore As Chief Operating Officer 2Synageva BioPharma Appoints Robert Bazemore As Chief Operating Officer 3Synageva BioPharma Appoints Robert Bazemore As Chief Operating Officer 4
... BEIJING , July 6 /PRNewswire-Asia-FirstCall/ ... the development, assembly, marketing and,sale of medical devices and homecare medical products ... sell 10,000 oxygen-chip units to,Beijing C&D Co., Ltd. for RMB11 million ... , , ...
... XIANYANG, China , July ... ) ("Biostar" or "the Company"), the,Xianyang-based manufacturer of a ... other pharmaceutical products, today,announced that Mr. Deyin "Bill" ... July 1, 2010 . Mr. Chen replaces Ms. ...
... ROCKVILLE, Md. , July 6 Novavax, Inc. ... Gregory Glenn , M.D., as the company,s Chief Scientific Officer ... and Chief Executive Officer of Novavax.  Previously, Dr. Glenn was ... an associate in international health at Johns Hopkins University,s ...
Cached Biology Technology:Dehaier Medical Systems Signs $1.6 Million Oxygen-Chip Sales Contract 2Dehaier Medical Systems Signs $1.6 Million Oxygen-Chip Sales Contract 3Dehaier Medical Systems Signs $1.6 Million Oxygen-Chip Sales Contract 4Biostar Pharmaceuticals, Inc. Appoints New Chief Financial Officer 2Biostar Pharmaceuticals, Inc. Appoints New Chief Financial Officer 3Novavax Announces Appointment of Dr. Gregory Glenn as Chief Scientific Officer 2Novavax Announces Appointment of Dr. Gregory Glenn as Chief Scientific Officer 3Novavax Announces Appointment of Dr. Gregory Glenn as Chief Scientific Officer 4
(Date:9/21/2014)... of children with autism are significantly less likely to ... than the mothers of children who are developing normally, ... Institute has found. , Low iron intake was associated ... child if the mother was 35 or older at ... suffered from metabolic conditions such as obesity hypertension or ...
(Date:9/21/2014)... immune T cells may have the ability to trigger ... study led by King,s College London. Although their immune ... may still be able to mount a strong immune ... Nature Medicine . , Our immune system is made ... neutrophils which play an important role in the frontline ...
(Date:9/19/2014)... A University of Oklahoma biology professor will study the ... analysis that could eventually benefit people,s health. The ... manage the energy required to produce the signals used ... generate electric signals at a rate of 500-600 discharges ... required for the electric fish are extreme, but necessary ...
Breaking Biology News(10 mins):Mothers of children with autism less likely to have taken iron supplements 2Immune system of newborn babies is stronger than previously thought 2
... Biological Sciences Research Council (BBSRC)-led Integrated Biorefining Research and ... which could be used to make biofuel production more ... Issue of the American Chemical Society journal Biochemistry ... the Universities of Warwick and British Columbia, could make ...
... Carolina State University have developed a new technique ... a computer,s ability to build computer models of ... algorithms used to build models of biological systems ... can account for uncertainty and biological variation. This ...
... Institute has won a four-year, $1.9 million grant from ... parasite that causes malaria, laying the groundwork to develop ... "Many antimalarial drugs alleviate symptoms, but do ... malaria parasites are able to persist asymptomatically in the ...
Cached Biology News:First wood-digesting enzyme found in bacteria could boost biofuel production 2New parallelization technique boosts our ability to model biological systems 2Scripps Research scientist wins $1.9 million grant to study malaria 2
Designed for use with the Agencourt SprintPrep 384 kit and all MCPrep reagent kits. Used with flat bottom 96-well microplates such as deep well plates used to culture bacteria....
ID clarifier: non-treated with lid...
... ClearSpin Filter is a novel disposable spin ... clarification of bacterial lysates in plasmid purification ... a novel, disposable spin filtration device especially ... lysates in plasmid purification procedures. The neutralized ...
... (or medium binding) polystyrene surface is ... through passive interactions,• Is suitable primarily ... such as antibodies, that have large ... the surface,• Binding capacity of approximately ...
Biology Products: